ISRCTN11434567进行中（未招募）3 期
ACTION III: A multi-country, multi-centre, three-arm, parallel group, double-blind, placebo-controlled, randomized trial of two doses of antenatal corticosteroids for women with a high probability of birth in the late preterm period in hospitals in low-resource countries to improve newborn outcomes
适应症
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 13,500
研究概览
简要总结
2024 Protocol article in https://pubmed.ncbi.nlm.nih.gov/38609983/ (added 15/04/2024)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Female
入选标准
- •The population of interest is women with singleton or multiple pregnancy at 34+0 weeks to 36+5 weeks and a high probability of late preterm birth (which extends up to 36 weeks 6 days). High probability of late preterm birth is defined as birth expected between 12 hours and 7 days
- •Inclusion criteria (all to be met):
- •1. Gestational age from 34 weeks 0 days to 36 weeks 5 days
- •2. High probability of late preterm birth (up to 36+6 weeks) defined as birth expected between 12 hours and 7 days after randomization as a result of:
- •2.1. Membrane rupture without preterm labour (where preterm labour is defined as at least 6 regular uterine contractions/ hr and at least one of the following: cervical dilatation of =3 cm or effacement =75%). OR
- •2.2. Preterm labour with intact membranes, defined as at least 6 regular contractions/hr and at least one of the following: (i) cervix =3cm dilated or (ii) 75% effaced; OR
- •2.3. Planned delivery by induction of labour or caesarean section between 24 hours and 7 days, as deemed necessary by the provider. An induction must be scheduled to start by 36+5 weeks at the latest, whereas a caesarean delivery must be scheduled by 36+6 weeks at the latest
- •3. Singleton or multiple pregnancies, where the foetus/es (or at least one foetus in a multiple pregnancy) is/are confirmed alive by doppler or ultrasonography
- •4. Women with no clinical signs of severe infection (as per obstetric care physician’s assessment)
- •5. Women willing and able to provide consent (or if a minor, provides assent and guardian provides consent)
排除标准
- •1. Ruptured membranes with cervix dilated =3 cm or effaced =75%, or with more than 6 contractions per hour (or both)
- •2. Cervical dilation =8 cm with intact membranes
- •3. Clinical suspicion or evidence of clinical chorioamnionitis or severe infection, as per obstetric care physician assessment
- •4. Evidence of non-reassuring foetal status requiring immediate delivery
- •5. Major or lethal congenital foetal anomaly identified
- •6. No prior ultrasound-based estimate of gestational age available and immediate ultrasound examination is not possible
- •7. Any systemic corticosteroid use during the current pregnancy (outside of trial)
- •8. Unwilling or unable to provide consent or assent (including due to active labour)
- •9. Currently a participant in another clinical trial related to maternal and neonatal health, or previously participated in any ACTION trial
- •10. Any other clinical indication where the treating clinician considers corticosteroids to be contraindicated
研究者
相似试验
进行中（未招募）
3 期
Renal Adjuvant Multiple Arm Randomised Trial (RAMPART)Resected primary renal cell carcinomaMalignant neoplasm of kidney, except renal pelvisCancerISRCTN53348826niversity College London1,750
尚未招募
4 期
The WHO ACTION (Antenatal CorticosTeroids for Improving Outcomes in Preterm Newborns) TrialsPACTR202105463874444World Health Organization2,520
进行中（未招募）
不适用
A parallel multi-centre randomised controlled trial to determine the clinical and cost-effectiveness of DREAMS START (Dementia RElAted Manual for Sleep; STrAtegies for RelaTives) for people living with dementia and their carersISRCTN13072268Camden and Islington NHS Foundation Trust740
进行中（未招募）
不适用
Can a nuclear medicine scan (MIBI-kidney) tell us if a mass in the kidney is cancer?CancerISRCTN12572202niversity College London150
进行中（未招募）
不适用
Autologous stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing-remitting multiple sclerosisMultiple sclerosisRelapsing-remitting multiple sclerosisNervous System DiseasesISRCTN88667898Sheffield Teaching Hospitals NHS Foundation Trust198